Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.

×

Foutmelding

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 53 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (regel 95 van /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.
Long title: 
Clinical trial (phase II) to evaluate the efficacy of MVANP+M1 in a human H3N2 influenza challenge model.
Date receipt dossier: 
14 jan 2019
EU record number: 
FLU10
EudraCT number: 
2018-004015-49
Pharmaceutical study code: 
MVA-NP+M1
Company / Sponsor: 
Vaccitech Limited
Phase: 
II
Treated organism: 
Humans
Indication category: 
Infectious disease
Disease: 
Influenza virus infection (seasonal flu)
Therapeutic approach: 
Prevention
Genetic modification: 
Vaccinia virus Ankara strain expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Method of transfer of nucleic acid of interest: 
Not applicable
Administered biological material: 
Recombinant vaccinia virus (MVA) expressing nucleoprotein (NP) and Matrix protein (M1) from influenza A H3N2 virus
Route of administration: 
Intramuscular
Locations in Belgium: 
SGS Belgium NV
Type of procedure: 
Contained use only
Current status: 
Authorized